Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Rising demands and advancements in eye care drive growth
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Subscribe To Our Newsletter & Stay Updated
